Kavita Juneja serves as the Head of Metabolic Therapeutic Development and Senior Director at Corcept Therapeutics since June 2022. Prior experience includes roles at Gilead Sciences, where Kavita was a Senior Director overseeing global development of remdesivir and served as clinical lead for significant COVID-19 studies. Kavita's career further encompasses leadership positions in metabolic disease research at Aegerion Pharmaceuticals, Novo Nordisk, and Texas A&M Health Science Center, alongside academic appointments at Dell Medical School and Washington University School of Medicine. Educational qualifications include a Doctor of Medicine from Vanderbilt University School of Medicine and a Bachelor’s Degree from The University of Texas at Austin.
This person is not in any teams
This person is not in any offices